
Understand how LH and FSH fit into a low-testosterone evaluation, including hormone patterns, fertility questions and further assessment.

LH and FSH are hormones called gonadotropins that clinicians measure to help assess testicular function and hormonal signaling. After a low testosterone finding, these blood tests help distinguish a pattern involving the testes from one involving signaling through the pituitary and hypothalamus.
Medical note: This article is for informational purposes and is not medical advice. A qualified clinician should interpret hormone results and guide individual evaluation or treatment.
A normal or elevated LH or FSH result describes where that measurement sits relative to a reference range. Its clinical meaning depends on the accompanying testosterone result and the reason for testing. The European Association of Urology (EAU) recommends measuring LH and FSH to help differentiate types of hypogonadism.
The useful distinction is between describing a laboratory result and explaining a clinical pattern. “Within range” describes the measurement. Understanding what that measurement represents biologically requires looking at the other hormone findings and the clinical assessment.
The EAU describes assessment of late-onset hypogonadism as requiring compatible signs and symptoms together with consistently low morning testosterone on at least two occasions. Testing should use a reliable assay in fasting conditions.
This separates two questions that can otherwise become mixed together:
LH and FSH mainly help with the second question. Their addition to a blood panel does not replace the confirmation process for testosterone. The sequence matters because investigating a possible cause is different from establishing the finding that needs explaining.
Our guide to the timing and preparation behind testosterone testing explains that earlier stage of the workup.
According to the EAU, LH and FSH help clinicians classify hypogonadism. That classification can direct attention toward testicular function or toward the hormonal signaling that involves the hypothalamus and pituitary.
These markers guide further assessment rather than identify every underlying cause by themselves. They also do not create an automatic indication for testosterone treatment.
For the reader, the important question is therefore not simply whether LH or FSH has been flagged. It is how the result changes the clinician’s understanding of the testosterone finding. A discussion of how related hormone measurements fit together can help make that distinction clearer.
The EAU also describes a compensated or subclinical pattern: normal serum testosterone with elevated LH. It states that the clinical significance of this pattern is unclear.
This is different from the confirmed-low-testosterone situation discussed above. A raised LH value and a normal testosterone value describe a different combination from a persistently low testosterone result. Keeping those situations separate prevents an isolated laboratory flag from being treated as though it answers the entire clinical question.
For adult men, symptoms remain part of the assessment even after LH and FSH have been measured. The EAU’s diagnostic approach combines compatible signs and symptoms with confirmed low morning testosterone. It does not replace the clinical picture with a gonadotropin result.
Low sexual desire is one symptom specifically named in the guideline’s recommendations for further testing. The EAU recommends prolactin testing when low sexual desire or other suggestive symptoms are present in the setting of secondary hypogonadism.
That recommendation connects the symptom history to a targeted part of the evaluation. It is not a reason to interpret every change in sexual desire as evidence of the same hormone problem. The clinical question remains how the symptoms fit the confirmed testosterone findings and the broader assessment.
Fertility concerns add another question. A man asking about low testosterone may also want to understand whether sperm production needs assessment. The EAU’s male-infertility guidance considers gonadotropins alongside testosterone when assessing testicular deficiency and classifying hypogonadism.
These are related concerns but different evaluation goals. Explaining the symptoms that prompted testing and raising fertility questions helps keep the discussion focused on what the workup is intended to assess. Our overview of what a medical evaluation involves provides additional context for that conversation.
The physiological factors relevant to these tests include testicular function and upstream hormone signaling. FSH also has a relationship with the stage and nature of impaired sperm development. The EAU guidance provides several useful distinctions.
The EAU male-infertility guideline associates elevated FSH with reduced or absent spermatogonia in some patterns of testicular deficiency. Spermatogonia are the cells named in this part of the guideline’s assessment of sperm development.
This gives an elevated FSH result a biological context. It may contribute information about testicular function that is different from the question answered by the testosterone measurement. That is why the infertility guidance considers gonadotropins together with testosterone rather than treating the measurements as interchangeable.
The same guideline notes that FSH may remain within the normal range when spermatogonia are present but maturation stops at a later stage. A normal FSH result therefore does not rule out impaired sperm production.
Taken together, these findings explain why FSH interpretation depends on the nature of the testicular impairment. Reduced or absent spermatogonia and later-stage maturation arrest are not the same biological situation. The hormone result needs to be understood in relation to the clinical question about fertility.
For someone concerned about fertility, the useful discussion is whether the assessment addresses sperm production as well as testosterone status. The goal is to clarify what each part of the evaluation contributes.
The other major area of investigation is signaling involving the hypothalamus and pituitary. The EAU recommends measuring LH alongside prolactin when a pathological total testosterone result is detected. It also gives separate recommendations for further evaluation in selected cases of secondary hypogonadism.
In that setting, the guideline recommends pituitary MRI when specified findings are present:
These criteria show how additional clinical or biochemical findings shape the investigation. The imaging recommendation belongs to a defined clinical setting rather than following automatically from an isolated gonadotropin value.
This is the practical role of follow-up hormone testing: it helps organize the next questions. The clinician uses the combined findings to decide which part of the hormonal system warrants closer attention and whether further assessment is appropriate.
Ask your physician: “Has my low testosterone been confirmed under the recommended conditions? How do my LH and FSH results fit that finding? Do my symptoms or fertility concerns make prolactin testing or further assessment appropriate?”
After an LH and FSH review, understanding the rest of a hormone report is a next educational step that Testostra addresses. Its biomarker coverage explains how measures such as SHBG and free testosterone fit beside total testosterone, supporting informed medical conversations rather than directing a reader’s individual care.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra